Kura Oncology, Inc.
Company Stats
- Market Cap
- $952.8M
- as of Sep 30, 2026
- Shares Outstanding
- 89.0M
- Free Float
- 97.7%
Income Statement
- Revenue
- $67.5M
- Operating Income
- -$303.6M
- Net Income
- -$278.7M
- EBITDA
- -$302.6M
Cash Flow
- Free Cash Flow
- -$70.7M
- FCF Yield
- -7.4%
- Owner FCF Yield
- -11.3%
Balance Sheet
- Cash & Equivalents
- $149.1M
Returns & Capital
- SBC, 3Y Avg
- $33.0M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | $67.5M | -$70.7M | -104.8% |
| FY2024 | $53.9M | $133.8M | 248.4% |
| FY2023 | $0 | -$125.0M | — |
| FY2022 | — | -$110.7M | — |
| FY2021 | — | -$105.7M | — |
Annual filing data through FY ended December 31, 2025; shares and float as of October 30, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Stronger demand supports expansion as pricing diverges